This method relies on the body’s own immune function and has become a prominent area of cancer treatment research.[15] In recent years, inhibitors targeting programmed death-1 (PD-1) and its ligand (PD-L1) have emerged as some of the most widely used immunotherapeutic agents in clinical practice, demonstrating significant efficacy in treating various types of cancer, including hypopharyngeal cancer. Here, CD274 is linked to hypopharynx cancer.